Acute leukemia – Talk Bio

FDA Approves Syndax’s First-in-Class Menin Inhibitor with Black-Box Warning; Updates on GSK’s ADC Deal

1 month ago talkbio0Tagged Acute leukemia, Antibody-Drug Conjugates, Approved, black-box warning, Chromosomal translocation, differentiation syndrome, KMT2A gene, Leukemia, Myelocytic, Acute, Menin Inhibitor, oncology drug approval, Revuforj, revumenib, SmithKline Beecham, Syndax, United States Food and Drug Administration

Syndax; Revuforj; revumenib; FDA approval; menin inhibitor; black-box warning; acute leukemia; KMT2A translocation; differentiation syndrome; acute myeloid leukemia (AML); GSK; antibody-drug conjugate (ADC); oncology drug approval

FDA Approves Revuforj, a First-in-Class Menin Inhibitor, for Relapsed or Refractory Acute Leukemia with KMT2A Translocation

1 year ago talkbio0Tagged Acute leukemia, Approved, Chromosomal translocation, KMT2A gene, Menin Inhibitor, Relapsing course, Revuforj, Syndax, United States Food and Drug Administration, Unresponsive to Treatment

FDA approval, Revuforj, Menin inhibitor, Acute leukemia, KMT2A translocation, Relapsed or refractory, Syndax Pharmaceuticals

Syndax’s Revumenib Shows Promising Results in Acute Leukemia Trials, Paving Way for FDA Approval

1 year ago talkbio0Tagged Acute leukemia, Approved, AUGMENT-101, beat, BEAT AML, Commit Operation, Leukemia, Myelocytic, Acute, revumenib, Syndax, United States Food and Drug Administration

Revumenib, Acute Leukemia, AUGMENT-101, SAVE Trial, BEAT AML, Syndax Pharmaceuticals, FDA Approval